Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Dose Escalating Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma

NCT00243763 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00243763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00243763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Dose Escalating Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma
Lead sponsor
Novartis
Phase
Phase 1
Overall status
Terminated
Start date
Not reported
Completion date
Not reported
Enrollment
64 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma